Related Experiment Video
Updated: Aug 11, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
H2-antagonists in the treatment of colon and breast cancer
1University of New South Wales, Department of Surgery, St George Hospital, Sydney, Australia.
Abstract:
Several clinical trials have now been carried out with histamine type 2 receptor antagonists in cancer patients often as an adjunct to surgical resection of the primary tumour While promising results have been obtained in some groups of patients with gastrointestinal cancer, with increased survival and evidence of increased immunological recognition of tumour, results are less encouraging for breast cancer. This may be due to differences in the levels of histamine or the role of histamine in growth of these different tumour types.
Insights
Histamine H2 receptor antagonists show promise for gastrointestinal cancer patients, improving survival and immune response. However, results are less encouraging for breast cancer, possibly due to histamine level differences.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Histamine type 2 receptor antagonists have been investigated in cancer treatment.
- Their use as an adjunct to primary tumor resection has been explored in clinical trials.
Purpose of the Study:
- To evaluate the efficacy of histamine type 2 receptor antagonists in cancer patients.
- To compare outcomes in different cancer types, specifically gastrointestinal and breast cancer.
Main Methods:
- Clinical trials involving cancer patients receiving histamine type 2 receptor antagonists.
- Assessment of patient survival and immunological recognition of tumors.
Main Results:
- Promising results observed in gastrointestinal cancer patients, including increased survival.
- Evidence of enhanced immunological recognition of tumors in some gastrointestinal cancer groups.
- Less encouraging results reported for breast cancer patients.
Conclusions:
- Histamine type 2 receptor antagonists may benefit certain cancer types, like gastrointestinal cancer.
- Differential responses between gastrointestinal and breast cancer suggest varying roles or levels of histamine.
- Further research is needed to elucidate the role of histamine in different tumor types.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...